Clinical Trials Logo

Smoldering Plasma Cell Myeloma clinical trials

View clinical trials related to Smoldering Plasma Cell Myeloma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05288062 Active, not recruiting - Plasma Cell Myeloma Clinical Trials

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Start date: March 22, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of immunomodulatory drug(s) in combination with a corticosteroid drug in treating patients with multiple myeloma or smoldering multiple myeloma. Immunomodulatory drugs such as lenalidomide and pomalidomide work through a variety of mechanisms to affect the function of the immune system. They are widely used as treatment for multiple myeloma and remain the backbone of therapy for both newly diagnosed patients and patients that have multiple myeloma that has come back after treatment (relapsed). Corticosteroid drugs like dexamethasone are strong anti-inflammatory agents that are also widely used to treat patients with multiple myeloma. This study may help doctors find out how patients respond to one treatment cycle of immunomodulatory drug(s) in combination with dexamethasone. This may help doctors determine which combinations of drugs work best in treating patients with multiple myeloma or smoldering multiple myeloma.

NCT ID: NCT04370483 Active, not recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

Start date: October 8, 2020
Phase: Early Phase 1
Study type: Interventional

This pilot trial studies how well leflunomide works for the treatment of patients with high-risk smoldering plasma cell myeloma, for the delay of disease progression. Anti-inflammatory drugs, such as leflunomide lower the body's immune response and are used with other drugs in the treatment of some types of cancer. The information learned from this study will help researchers to learn more about the anti-myeloma activity of leflunomide, and whether it may delay the onset of symptomatic multiple myeloma in patients with high-risk smoldering multiple myeloma.

NCT ID: NCT03631043 Active, not recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Start date: December 21, 2018
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.

NCT ID: NCT02960555 Active, not recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

Start date: February 8, 2017
Phase: Phase 2
Study type: Interventional

This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.

NCT ID: NCT02603887 Active, not recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

Start date: July 20, 2016
Phase: Early Phase 1
Study type: Interventional

This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.